在帕金森病患者的血清中,神经丰富的微粒RNAs具有差异性表达
Morris A Aguilar1,2, Shauna Ebanks3, Havell Markus3
1Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA, United States.
Frontiers in neuroscience
|July 24, 2023
概括
在神经元丰富的血清外体和微囊中,小RNA (smRNA) 档案在帕金森病 (PD) 患者中显示出明显的差异. 这些smRNA可以有效地将PD受试者与健康对照者区分开来,提供潜在的诊断生物标志物.
科学领域:
- 生物化学 生化学
- 基因组学就是基因组学.
- 神经科学是一个神经科学.
背景情况:
- 循环小RNAs (smRNAs) 越来越多地被研究为潜在的生物标志物.
- 以前对帕金森病 (PD) 生物标志物的smRNA的研究产生了不一致的结果.
- 调查神经元丰富的血清外体和微,以发现与PD相关的smRNA变化.
研究的目的:
- 为了确定神经元丰富的血清外体和微囊中的smRNA概况是否在PD患者中发生变化.
- 评估这些smRNA配置文件对PD受试者与对照者进行歧视的能力.
主要方法:
- 分析了来自60名PD患者和40名对照组的血清样本.
- 用CD171神经元标记物分离出外体和微粒细胞.
- 使用了测序,生物信息学,物流回归和随机森林模型.
主要成果:
- 在PD患者中确定了29个差异表达smRNA的小组 (FDR<0.05).
- 四个smRNA显示高分辨值 (AUC≥0.74);29个smRNA小组实现了0.942.9的AUC.
- 途径分析表明与细胞增殖调节和信号传递有联系.
结论:
- 富含CD171的外体和微囊细胞在PD和对照组之间具有差异性的smRNA表达.
- 这些发现强调了外体smRNA作为PD生物标志物的潜力.
- 需要进一步的研究来确定这些smRNA变化的临床相关性.
关键词:
帕金森病是帕金森氏症的一种疾病.生物标志物 生物标志物外基因组是外基因组中的一个.微微的微小的微小的微小的微小的微小随机的森林随机的森林这是一个回归回归的回归.小小的RNARNA小小的RNARNA.更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.6K
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.8K
相关概念视频
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:15Parkinson's Disease: Overview
601
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
601